Literature DB >> 26109735

Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study.

M V Dieci1, C Criscitiello2, A Goubar3, G Viale4, P Conte5, V Guarneri5, G Ficarra6, M C Mathieu7, S Delaloge8, G Curigliano2, F Andre9.   

Abstract

Entities:  

Year:  2015        PMID： 26109735      PMCID： PMC5266091          DOI： 10.1093/annonc/mdv241

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  14 in total

Review 1.  Biology and Management of Patients With Triple-Negative Breast Cancer.

Authors:  Priyanka Sharma
Journal:  Oncologist       Date:  2016-07-11

2.  Biomarkers of immunogenic stress in metastases from melanoma patients: Correlations with the immune infiltrate.

Authors:  Sylvain Ladoire; Laura Senovilla; David Enot; François Ghiringhelli; Vichnou Poirier-Colame; Kariman Chaba; Gulsun Erdag; Jochen T Schaefer; Donna H Deacon; Laurence Zitvogel; Craig L Slingluff; Guido Kroemer
Journal:  Oncoimmunology       Date:  2016-03-16       Impact factor: 8.110

3.  The ratio of CD8+/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ.

Authors:  Michaela Semeraro; Julien Adam; Gautier Stoll; Emilie Louvet; Kariman Chaba; Vichnou Poirier-Colame; Allan Sauvat; Laura Senovilla; Erika Vacchelli; Norma Bloy; Juliette Humeau; Aitziber Buque; Oliver Kepp; Laurence Zitvogel; Fabrice André; Marie-Christine Mathieu; Suzette Delaloge; Guido Kroemer
Journal:  Oncoimmunology       Date:  2016-08-18       Impact factor: 8.110

Review 4.  Advancing Immunotherapy in Metastatic Breast Cancer.

Authors:  Mariam Mansour; Zhi Ling Teo; Stephen J Luen; Sherene Loi
Journal:  Curr Treat Options Oncol       Date:  2017-06

Review 5.  Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast Cancer.

Authors:  Barbara Ingold Heppner; Sibylle Loibl; Carsten Denkert
Journal:  Breast Care (Basel)       Date:  2016-04-26       Impact factor: 2.860

Review 6.  Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.

Authors:  Sasagu Kurozumi; Takaaki Fujii; Hiroshi Matsumoto; Kenichi Inoue; Masafumi Kurosumi; Jun Horiguchi; Hiroyuki Kuwano
Journal:  Med Mol Morphol       Date:  2017-09-21       Impact factor: 2.309

7.  Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy.

Authors:  Reza Nejati; Jennifer B Goldstein; Daniel M Halperin; Hua Wang; Nazila Hejazi; Asif Rashid; Matthew H Katz; Jeffrey E Lee; Jason B Fleming; Jaime Rodriguez-Canales; Jorge Blando; Ignacio I Wistuba; Anirban Maitra; Robert A Wolff; Gauri R Varadhachary; Huamin Wang
Journal:  Pancreas       Date:  2017-10       Impact factor: 3.327

8.  The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer.

Authors:  Sylvain Ladoire; David Enot; Laura Senovilla; François Ghiringhelli; Vichnou Poirier-Colame; Kariman Chaba; Michaela Semeraro; Marie Chaix; Frédérique Penault-Llorca; Laurent Arnould; Marie Laure Poillot; Patrick Arveux; Suzette Delaloge; Fabrice Andre; Laurence Zitvogel; Guido Kroemer
Journal:  Autophagy       Date:  2016-03-16       Impact factor: 16.016

9.  VEGF-A Is Associated With the Degree of TILs and PD-L1 Expression in Primary Breast Cancer.

Authors:  Takaaki Fujii; Tomoko Hirakata; Sasagu Kurozumi; Shoko Tokuda; Yuko Nakazawa; Sayaka Obayashi; Reina Yajima; Tetsunari Oyama; Ken Shirabe
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

Review 10.  NHERF1 Between Promises and Hopes: Overview on Cancer and Prospective Openings.

Authors:  Matteo Centonze; Concetta Saponaro; Anita Mangia
Journal:  Transl Oncol       Date:  2018-02-20       Impact factor: 4.243
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.